37 results on '"Chatterton, Kathryn"'
Search Results
2. Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence
3. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes
4. sj-pdf-1-inq-10.1177_00469580211030217 – Supplemental material for Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience
5. Is there a role for physical activity interventions in the treatment pathway of bladder cancer? : A scoping review of the literature
6. Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience
7. The need for supportive mental wellbeing interventions in bladder cancer patients : A systematic review of the literature
8. SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) MITOMYCIN C (MMC) AS THE STANDARD INTRAVESICAL REGIMEN IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) – ONE YEAR OUTCOMES: MP56-15
9. LONG TERM FOLLOW UP OF A PROSPECTIVE RANDOMISED TRIAL OF HEXYLAMINOLEVULINATE (HEXVIX®) PHOTODYNAMIC DIAGNOSIS (PDD) ASSISTED VERSUS CONVENTIONAL WHITE-LIGHT TRANSURETHRAL RESECTION (TURBT) IN NEWLY PRESENTING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC): MP22-08
10. Is there a role for physical activity interventions in the treatment pathway of bladder cancer? A scoping review of the literature
11. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer
12. The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature
13. Safety of “hot” and “cold” site admissions within a high‐volume urology department in the United Kingdom at the peak of the COVID‐19 pandemic
14. Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience
15. Demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces long-term regret: a comparative cohort study
16. Safety of ‘hot’ and ‘cold’ site admissions within a high volume urology department in the United Kingdom at the peak of the COVID-19 pandemic
17. Improving management of upper tract urothelial carcinoma
18. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin
19. Hexylaminolaevulinate ‘blue light’ fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology
20. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method
21. Graham Roberts Study protocol: first ‘trials within cohort study’ for bladder cancer
22. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method
23. Will long-term disease specific outcomes of bladder conservation with sequential Bacillus Calmette-Guérin (BCG) and electromotive drug administration Mitomycin-C (EMDA-MMC) for high-risk non-muscle invasive bladder cancer (HR-NMIBC) influence adoption?
24. A pilot study to evaluate patient reported outcome measures of bladder cancer patients undergoing radical cystectomy at Guy’s and St Thomas’ NHS Foundation Trust.
25. PD19-06 HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP
26. MP22-08 LONG TERM FOLLOW UP OF A PROSPECTIVE RANDOMISED TRIAL OF HEXYLAMINOLEVULINATE (HEXVIX®) PHOTODYNAMIC DIAGNOSIS (PDD) ASSISTED VERSUS CONVENTIONAL WHITE-LIGHT TRANSURETHRAL RESECTION (TURBT) IN NEWLY PRESENTING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
27. MP56-15 SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) MITOMYCIN C (MMC) AS THE STANDARD INTRAVESICAL REGIMEN IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) – ONE YEAR OUTCOMES
28. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi
29. Demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces long-term regret: a comparative cohort study
30. 1754 CHALLENGING UROLOGICAL GUIDELINES – ASSESSING THE YIELD FROM EARLY RE-RESECTIONS IN A CONTEMPORARY COHORT OF PATIENTS MANAGED WITH HIGH QUALITY INITIAL TRANSURETHRAL RESECTION (TURBT) BY A SPECIALIST BLADDER CANCER TEAM
31. 1647 A PROSPECTIVE RANDOMISED TRIAL OF HEXYLAMINOLEVULINATE (HAL) ASSISTED TRANSURETHRAL RESECTION (TURBT) PLUS SINGLE SHOT INTRAVESICAL MITOMYCINC (MMC) VERSUS WHITE LIGHT TURBT PLUS SINGLE SHOT MMC IN NEWLY PRESENTING BLADDER CANCER
32. Hexylaminolevulinate Photodynamic Diagnosis for Multifocal Recurrent Nonmuscle Invasive Bladder Cancer
33. Improving Bladder Cancer Outcomes: The Impact of Initiating a Phase IV Randomised Controlled Clinical Trial
34. 1583: The True Value of Hexvix® Photodynamic Diagnosis Following Intravesical Bacille Calmette Guerin Treatment for Superficial Bladder Cancer
35. Nurses' experience establishing a nurse-led bladder cancer surveillance flexible cystoscopy service.
36. Improving Bladder Cancer Outcomes: The Impact of Initiating a Phase IV Randomised Controlled Clinical Trial
37. Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.